Media ReleasesImmutep

View All Immutep News

Immutep - Efti with Keytruda shows encouraging activity in lung cancer

* All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory)
* Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 months
* 73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration compared to pre-study situation
* Encouraging preliminary Overall Survival (OS) at the 6-month landmark, with a 73% survival rate
* 5.6% of patients (2/36) had confirmed and durable partial responses, with both patients continuing in the trial for over 9 months and 23 months, well beyond expectations
* Efti continues to be safe and well tolerated 

SYDNEY, AUSTRALIA – 30 March 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data in 2nd line metastatic NSCLC from its Phase II TACTI002 trial. The data was published in a poster presentation today at ESMO’s European Lung Cancer Congress (ELCC) 2022 in Prague, Czech Republic and is also available on the Company’s website: 

This part of TACTI-002, known as Part B, evaluates Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s KEYTRUDA® (pembrolizumab) in a total of 36 patients with PD-L1 unselected 2nd line PD-X refractory metastatic NSCLC. The new data reflects the first interim results combining Stages 1 (23 patients) and 2 (13 patients) in 2nd line NSCLC.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.